News & Views | Published:

PROSTATE CANCER

Therapy-induced small-cell disease: from mouse to man and back

With the emergence of increasingly potent androgen deprivation therapy, rates of treatment-emergent small-cell neuroendocrine prostate cancer are increasing. In a recent prospective study, Aggarwal and colleagues defined the frequency and clinical and genomic characteristics of these tumours.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    Nuhn, P. et al. Update on systemic prostate cancer therapies: management of metastatic castration-resistant prostate cancer in the era of precision oncology. Eur. Urol. https://doi.org/10.1016/j.eururo.2018.03.028 (2018).

  2. 2.

    Davies, A. H., Beltran, H. & Zoubeidi, A. Cellular plasticity and the neuroendocrine phenotype in prostate cancer. Nat. Rev. Urol. 15, 271–286 (2018).

  3. 3.

    Mosquera, J. M. et al. Concurrent AURKA and MYCN gene amplifications are harbingers of lethal treatment-related neuroendocrine prostate cancer. Neoplasia 15, 1–10 (2013).

  4. 4.

    di Sant’Agnese, P. A. Neuroendocrine differentiation in human prostatic carcinoma. Hum. Pathol. 23, 287–296 (1992).

  5. 5.

    Aggarwal, R. et al. Clinical and genomic characterization of treatment-emergent small-cell neuroendocrine prostate cancer: a multi-institutional prospective study. J. Clin. Oncol. 36, 2492–2503 (2018).

  6. 6.

    Hu, C.-D., Choo, R. & Huang, J. Neuroendocrine differentiation in prostate cancer: a mechanism of radioresistance and treatment failure. Front. Oncol. 5, 90 (2015).

  7. 7.

    Bluemn, E. G. et al. Androgen receptor pathway-independent prostate cancer is sustained through FGF signaling. Cancer Cell 32, 474–489 (2017).

  8. 8.

    Jin, R. J. et al. NE-10 neuroendocrine cancer promotes the LNCaP xenograft growth in castrated mice. Cancer Res. 64, 5489–5495 (2004).

  9. 9.

    Grabowska, M. M. et al. Mouse models of prostate cancer: picking the best model for the question. Cancer Metastasis Rev. 33, 377–397 (2014).

  10. 10.

    Gupta, A. et al. Neuroendocrine differentiation in the 12T-10 transgenic prostate mouse model mimics endocrine differentiation of pancreatic beta cells. Prostate 68, 50–60 (2008).

Download references

Author information

Competing interests

The authors declare no competing interests.

Correspondence to Robert J. Matusik.

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark
Fig. 1: Transdifferentiation to treatment-induced small-cell neuroendocrine prostate cancer.